Cytomegalovirus-vectored vaccines for HIV and other pathogens

Peter A. Barry, Jesse D. Deere, Yujuan Yue, William W.L. Chang, Kimberli A. Schmidt, Felix Wussow, Flavia Chiuppesi, Don J. Diamond, Ellen E. Sparger, Mark R. Walter, Dennis J. Hartigan-O'Connor

Research output: Contribution to journalReview article

Abstract

The use of cytomegalovirus (CMV) as a vaccine vector to express antigens against multiple infectious diseases, including simian immunodeficiency virus, Ebola virus, plasmodium, and mycobacterium tuberculosis, in rhesus macaques has generated extraordinary levels of protective immunity against subsequent pathogenic challenge. Moreover, the mechanisms of immune protection have altered paradigms about viral vector-mediated immunity against ectopically expressed vaccine antigens. Further optimization of CMV-vectored vaccines, particularly as this approach moves to human clinical trials will be augmented by a more complete understanding of how CMV engenders mechanisms of immune protection. This review summarizes the particulars of the specific CMV vaccine vector that has been used to date (rhesus CMV strain 68-1) in relation to CMV natural history.

Original languageEnglish (US)
Pages (from-to)335-349
Number of pages15
JournalAIDS
Volume34
Issue number3
DOIs
StatePublished - Mar 1 2020

    Fingerprint

Keywords

  • AIDS
  • Cytomegalovirus
  • Cytomegalovirus vaccine vector
  • HIV
  • Monkey model
  • Nonhuman primate
  • Rhesus
  • Rhesus cytomegalovirus
  • Simian immunodeficiency virus
  • Unconventional T-cell responses

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Barry, P. A., Deere, J. D., Yue, Y., Chang, W. W. L., Schmidt, K. A., Wussow, F., Chiuppesi, F., Diamond, D. J., Sparger, E. E., Walter, M. R., & Hartigan-O'Connor, D. J. (2020). Cytomegalovirus-vectored vaccines for HIV and other pathogens. AIDS, 34(3), 335-349. https://doi.org/10.1097/QAD.0000000000002396